- Home
- UAA vs APLS Comparison
UAA vs APLS Comparison
Compare UAA & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAA | APLS |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United States |
| Employees | 14400 | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | UAA | APLS |
|---|---|---|
| Price | $6.13 | $17.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 21 |
| Target Price | $6.48 | ★ $31.65 |
| AVG Volume (30 Days) | ★ 9.6M | 1.8M |
| Earning Date | 02-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.72 | $18.21 |
| P/E Ratio | ★ N/A | $89.68 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $4.13 | $16.10 |
| 52 Week High | $8.15 | $30.48 |
Technical Indicators
Market Signals| Indicator | UAA | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 36.09 | 27.58 |
| Support Level | $6.06 | $17.16 |
| Resistance Level | $6.50 | $20.42 |
| Average True Range (ATR) | 0.29 | 0.73 |
| MACD | -0.14 | -0.16 |
| Stochastic Oscillator | 1.77 | 12.94 |
Price Performance
Historical ComparisonAbout UAA Under Armour Inc.
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.